Published online before print February 19, 2007, doi: 10.1161/01.HYP.0000259805.18468.8c
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2007;49:839.)
© 2007 American Heart Association, Inc.
Original Articles |
Effect of Spironolactone on Blood Pressure in Subjects With Resistant Hypertension
From the Imperial College (N.C., J.D., S.W., P.S.S., N.R.P.), London, United Kingdom; the Sahlgrenska University Hospital (B.D.), Göteborg, Sweden; and the Nordic School of Public Health (H.W.), Göteborg, Sweden.
Correspondence to Neil Chapman, International Centre for Circulatory Health, Imperial College London, 59 North Wharf Rd, London W2 1PG, United Kingdom. E-mail neil.chapman{at}st-marys.nhs.uk
Spironolactone is recommended as fourth-line therapy for essential hypertension despite few supporting data for this indication. We evaluated the effect among 1411 participants in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm who received spironolactone mainly as a fourth-line antihypertensive agent for uncontrolled blood pressure and who had valid BP measurements before and during spironolactone treatment. Among those who received spironolactone, the mean age was 63 years (SD: ±8 years), 77% were men, and 40% had diabetes. Spironolactone was initiated a median of 3.2 years (interquartile range: 2.0 to 4.4 years) after randomization and added to a mean of 2.9 (SD: ±0.9) other antihypertensive drugs. The median duration of spironolactone treatment was 1.3 years (interquartile range: 0.6 to 2.6 years). The median dose of spironolactone was 25 mg (interquartile range: 25 to 50 mg) at both the start and end of the observation period. During spironolactone therapy, mean blood pressure fell from 156.9/85.3 mm Hg (SD: ±18.0/11.5 mm Hg) by 21.9/9.5 mm Hg (95% CI: 20.8 to 23.0/9.0 to 10.1 mm Hg; P<0.001); the BP reduction was largely unaffected by age, sex, smoking, and diabetic status. Spironolactone was generally well tolerated; 6% of participants discontinued the drug because of adverse effects. The most frequent adverse events were gynecomastia or breast discomfort and biochemical abnormalities (principally hyperkaliemia), which were recorded as adverse events in 6% and 2% of participants, respectively. In conclusion, spironolactone effectively lowers blood pressure in patients with hypertension uncontrolled by a mean of 
3 other drugs. Although nonrandomized and not placebo controlled, these data support the use of spironolactone in uncontrolled hypertension.
Key Words: blood pressure • hypertension • clinical trial • antihypertensive agents • aldosterone antagonists • spironolactone
Related Article:
Hypertension 2007 49: 763-764.
This article has been cited by other articles:
 |
|
 |
|
  N. R. Poulter Selecting a fixed combination to improve morbidity/mortality: the weight of evidence with ASCOT Eur. Heart J. Suppl., September 1, 2008; 10(suppl_G): G21 - G28. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Brown Aliskiren Circulation, August 12, 2008; 118(7): 773 - 784. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Ruilope Aldosterone, Hypertension, and Cardiovascular Disease: An Endless Story Hypertension, August 1, 2008; 52(2): 207 - 208. [Full Text] [PDF]
|
|
|
|
 |
|
 B. J Epstein Efficacy and Safety of Darusentan: A Novel Endothelin Receptor Antagonist Ann. Pharmacother., July 1, 2008; 42(7): 1060 - 1069. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. K. Gaddam, M. K. Nishizaka, M. N. Pratt-Ubunama, E. Pimenta, I. Aban, S. Oparil, and D. A. Calhoun Characterization of Resistant Hypertension: Association Between Resistant Hypertension, Aldosterone, and Persistent Intravascular Volume Expansion Arch Intern Med, June 9, 2008; 168(11): 1159 - 1164. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Williams The year in hypertension. J. Am. Coll. Cardiol., May 6, 2008; 51(18): 1803 - 1817. [Full Text] [PDF]
|
|
|
|
|
|
A. W. Krug and M. Ehrhart-Bornstein Aldosterone and Metabolic Syndrome: Is Increased Aldosterone in Metabolic Syndrome Patients an Additional Risk Factor? Hypertension, May 1, 2008; 51(5): 1252 - 1258. [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. C. Connell, S. M. MacKenzie, E. M. Freel, R. Fraser, and E. Davies A Lifetime of Aldosterone Excess: Long-Term Consequences of Altered Regulation of Aldosterone Production for Cardiovascular Function Endocr. Rev., April 1, 2008; 29(2): 133 - 154. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Davies, C. Hu, N. A. Guagliardo, N. Sen, X. Chen, E. M. Talley, R. M. Carey, D. A. Bayliss, and P. Q. Barrett TASK channel deletion in mice causes primary hyperaldosteronism PNAS, February 12, 2008; 105(6): 2203 - 2208. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. F. E. Mann What's new in hypertension 2007? Nephrol. Dial. Transplant., February 1, 2008; 23(2): 466 - 470. [Full Text] [PDF]
|
|
|
|
|
|
R. J. Auchus and M. H. Drazner Will the Lessons From Primary Aldosteronism Change the Treatment of Hypertension and Left Ventricular Hypertrophy? Hypertension, November 1, 2007; 50(5): 837 - 839. [Full Text] [PDF]
|
|
|
|
|
|
A. Delgado-Almeida Unexpected Therapeutic Response to Spironolactone: A Prospective Debate on Aldosterone and Potassium Ion in Hypertension Hypertension, November 1, 2007; 50(5): e165 - e164. [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. Rigsby, A. E. Burch, S. Ogbi, D. M. Pollock, and A. M. Dorrance Intact female stroke-prone hypertensive rats lack responsiveness to mineralocorticoid receptor antagonists Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2007; 293(4): R1754 - R1763. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Feely and A. Mahmud Spironolactone in Resistant Hypertension Hypertension, September 1, 2007; 50(3): e57 - e57. [Full Text] [PDF]
|
|
|
|
|
|
D. A. Calhoun and N. M. Kaplan Is There an Unrecognized Epidemic of Primary Aldosteronism? (Pro) Hypertension, September 1, 2007; 50(3): 447 - 453. [Full Text] [PDF]
|
|
|
|
|
|
N. M. Kaplan and D. A. Calhoun Is There an Unrecognized Epidemic of Primary Aldosteronism? (Con) Hypertension, September 1, 2007; 50(3): 454 - 458. [Full Text] [PDF]
|
|
|
|
|
|
S. J. Hood, K. P. Taylor, M. J. Ashby, and M. J. Brown The Spironolactone, Amiloride, Losartan, and Thiazide (SALT) Double-Blind Crossover Trial in Patients With Low-Renin Hypertension and Elevated Aldosterone-Renin Ratio Circulation, July 17, 2007; 116(3): 268 - 275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. L. Goodfriend Treating Resistant Hypertension With a Neglected Old Drug Hypertension, April 1, 2007; 49(4): 763 - 764. [Full Text] [PDF]
|
|